Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Acquisitions & Divestments (2023 - 2025)

CG Oncology filings provide 3 years of Change in Acquisitions & Divestments readings, the most recent being $222.2 million for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 2.6% to $222.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $844.1 million, a 13.24% increase, with the full-year FY2025 number at $844.1 million, up 13.24% from a year prior.
  • Change in Acquisitions & Divestments hit $222.2 million in Q4 2025 for CG Oncology, down from $251.4 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $251.4 million in Q3 2025 to a low of $30.7 million in Q3 2023.
  • Median Change in Acquisitions & Divestments over the past 3 years was $200.7 million (2024), compared with a mean of $185.0 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: surged 556.36% in 2024 and later dropped 2.6% in 2025.
  • CG Oncology's Change in Acquisitions & Divestments stood at $230.0 million in 2023, then dropped by 0.81% to $228.2 million in 2024, then fell by 2.6% to $222.2 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $222.2 million (Q4 2025), $251.4 million (Q3 2025), and $170.4 million (Q2 2025) per Business Quant data.